Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

Abstract Background The phase III REMoxTB study prospectively enrolled HIV-positive (with CD4+ count > 250 cells, not on anti-retroviral therapy) and HIV-negative patients. We investigated the incidence of adverse events and cure rates according to HIV status for patients receiving standard TB th...

Full description

Bibliographic Details
Main Authors: Conor D. Tweed, Angela M. Crook, Rodney Dawson, Andreas H. Diacon, Timothy D. McHugh, Carl M. Mendel, Sarah K. Meredith, Lerato Mohapi, Michael E. Murphy, Andrew J. Nunn, Patrick P. J. Phillips, Kasha P. Singh, Melvin Spigelman, Stephen H. Gillespie
Format: Article
Language:English
Published: BMC 2019-08-01
Series:BMC Pulmonary Medicine
Subjects:
Tuberculosis
Clinical trials
HIV
Adverse events
Online Access:http://link.springer.com/article/10.1186/s12890-019-0907-6

Internet

http://link.springer.com/article/10.1186/s12890-019-0907-6

Similar Items